SUPN — Supernus Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $2.30bn
- $1.93bn
- $718.95m
Deals of the day-Mergers and acquisitions
Sage Therapeutics jumps to over 10-month high after Supernus Pharma's buyout offer
Deals of the day-Mergers and acquisitions
Sage Therapeutics jumps after Supernus Pharma's buyout offer
Brief: Supernus Pharmaceuticals To Acquire Sage Therapeutics, Strengthening Its Neuropsychiatry Product Portfolio
Supernus Pharma to acquire Sage Therapeutics in up to $795 million deal (updated)
Supernus Pharma to acquire Sage Therapeutics in up to $795 million deal
Supernus Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Supernus Pharmaceuticals Q4 Product Sales USD 166.4 Million
U.S. STOCKS ON THE MOVE-Charles River Lab, Carvana, Materion
U.S. STOCKS ON THE MOVE-Travelers, Capri, Garmin
U.S. STOCKS ON THE MOVE-Bumble, Nikola, Diversified Energy
U.S. STOCKS ON THE MOVE-Compass, Penumbra, Bumble
Supernus Pharma sinks after depression drug fails mid-stage trial goal
Brief: Supernus Announces Topline Results From Phase 2B Study In Adults With Treatment Resistant Depression
Supernus' depression treatment fails mid-stage trial, shares plunge (updated)
Supernus' depression treatment fails mid-stage trial
U.S. STOCKS ON THE MOVE-US energy firms, Lancaster Colony, Xylem
Supernus rises after FDA approves its drug-device combination for Parkinson's disease